title: The efficacy and safety of concurrent chemoradiotherapy for maxillary sinus squamous cell carcinoma patients.
abstract: OBJECTIVE
  Combined treatment modality, e.g., definitive surgery followed by radiotherapy (RT) and definitive RT with concurrent chemotherapy, has been applied for advanced maxillary sinus squamous cell carcinoma (MSSCC) patients to obtain a better survival with organ preservation in Japan.
  
  
  METHODS
  The outcome of 40 patients with MSSCC between 1991 and 2007 in our institute was analyzed retrospectively. There were 36 males and 4 females, the average age being 59.5 years (ranging from 34 to 81 years). The median follow-up time was 66.1 months. All the patients had received a combined treatment consisting of definitive surgery, RT, and intra-arterial or systemic chemotherapy. The chemotherapeutic regimen was different depending on the performance status and/or complications of the patients. Since 1998, concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin regimen (CCRT-PFML) instead of neo-adjuvant chemotherapy has been applied.
  
  
  RESULTS
  The overall 5-year survival rate was 59.2%, the 5-year disease-specific survival rate was 71.7%, and the 5-year organ preservation survival rate was 42.4%. In the group receiving CCRT-PFML, the overall 5-year survival rate was 60.0%, the 5-year disease-specific survival rate was 76.0%, and the 5-year organ preservation survival rate was 60.3%.
  
  
  CONCLUSIONS
  CCRT-PFML for advanced MSSCC patients is feasible to preserve the organs without reducing the survival rate.
authors.affiliation: Department of Biology and Function in the Head and Neck, Yokohama City University Graduate School of Medicine, Fukuura, Kanazawa-ku, Japan. gnishimu@yokohama-cu.ac.jp
authors.forename: Goshi
authors.initials: G
authors.lastname: Nishimura
authors.forename: Mamoru
authors.initials: M
authors.lastname: Tsukuda
authors.forename: Yasukazu
authors.initials: Y
authors.lastname: Mikami
authors.forename: Hideki
authors.initials: H
authors.lastname: Matsuda
authors.forename: Choichi
authors.initials: C
authors.lastname: Horiuchi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Satake
authors.forename: Takahide
authors.initials: T
authors.lastname: Taguchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Mariko
authors.initials: M
authors.lastname: Kawakami
authors.forename: Hideaki
authors.initials: H
authors.lastname: Hanamura
authors.forename: Makiko
authors.initials: M
authors.lastname: Watanabe
authors.forename: Ai
authors.initials: A
authors.lastname: Utsumi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000009:adverse effects*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008443:Maxillary Sinus; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009926:Organ Preservation / Q000379:methods; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D005641:Tegafur; D014498:Uracil; D016190:Carboplatin; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil; D008727:Methotrexate